Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 363 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Overactive Clear all
Completed Phase 2 Interventional

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

NCT06206512
View directory record Official record
Conditions
Heart Failure, Overactive Bladder, Incontinence
Interventions
Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo, Immediate release torsemide placebo
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 7:19 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

NCT05534412
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Animated Videos to Foster Healthy Bladder Behaviors in Community Women

NCT06921915
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
eLearning
Other
Lead sponsor
Kathleen O'Connell
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated Not applicable Interventional

Group Medical Visits for Latina Women With Urgency Urinary Incontinence

NCT03687164
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency, Urge Incontinence
Interventions
Group Medical Visits
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Combined Behavioral and Drug Treatment of Overactive Bladder in Men

NCT01175382
View directory record Official record
Conditions
Overactive Bladder, Lower Urinary Tract Symptoms
Interventions
Behavioral training, Tolterodine + tamsulosin, Combined Behavioral + Drug Therapy
Behavioral · Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 22, 2026, 7:19 AM EDT
Completed No phase listed Observational

The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections

NCT04479709
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
60 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 22, 2026, 7:19 AM EDT
Recruiting No phase listed Observational

Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections

NCT07025044
View directory record Official record
Conditions
Overactive Bladder (OAB), Urge Incontinence
Interventions
onabotulinum toxin type a
Drug
Lead sponsor
Alexis Dieter
Other
Eligibility
55 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 22, 2026, 7:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

NCT05519072
View directory record Official record
Conditions
Antibiotic Prophylaxis
Interventions
Nitrofurantoin
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 22, 2026, 7:19 AM EDT
Not listed Early Phase 1 Interventional

Repetitive Transcranial Magnetic Stimulation in Women With Overactive Bladder With Urgency Incontinence

NCT05099419
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated Phase 4 Interventional Results available

Tetra-NIRS Clinical Study

NCT00871975
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder
Interventions
Urodynamics + TETRA - NIRS
Device
Lead sponsor
Laborie Medical Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 22, 2026, 7:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency

NCT01933074
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 22, 2026, 7:19 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Development of Novel Cystometrics for Overactive Bladder

NCT02060214
View directory record Official record
Conditions
Urinary Frequency/Urgency
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
22 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 22, 2026, 7:19 AM EDT
Recruiting No phase listed Observational

Noninvasive Ultrasound Assessment of Detrusor Dysfunction

NCT05652023
View directory record Official record
Conditions
Bladder Dysfunction, Overactive Bladder, BPH With Urinary Obstruction
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
2,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 7:19 AM EDT
Withdrawn Not applicable Interventional

Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder

NCT03753750
View directory record Official record
Conditions
Overactive Bladder, Incontinence, Urge, Neurogenic Bladder
Interventions
Noninvasive spinal cord stimulation
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

NCT00902187
View directory record Official record
Conditions
Treatment of Overactive Bladder
Interventions
Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

NCT01777217
View directory record Official record
Conditions
Over-Active Bladder
Interventions
Solifenacin succinate, Placebo
Drug
Lead sponsor
Advanced Research Network
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Not applicable Interventional

FemPulse Therapy for Overactive Bladder in Women

NCT03784170
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
FemPulse System
Device
Lead sponsor
FemPulse Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Woodbury, Minnesota • Charlotte, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
75
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 22, 2026, 7:19 AM EDT
Completed Phase 2 Interventional Results available

SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)

NCT00409539
View directory record Official record
Conditions
Overactive Bladder Syndrome (OABS)
Interventions
Placebo, SMP-986
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
20 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
21
States / cities
Tuscon, Arizona • Atherton, California • San Bernadino, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated Phase 2 Interventional Results available

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

NCT02462837
View directory record Official record
Conditions
Urinary Bladder, Overactive, Pain, Lower Urinary Tract Symptoms
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 22, 2026, 7:19 AM EDT
Terminated No phase listed Observational

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

NCT01099345
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry (CMG), polysomnography (PSG)
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 22, 2026, 7:19 AM EDT